Incidence and Predictors of Gastric Neoplastic Lesions in Corpus-Restricted Atrophic Gastritis: A Single-Center Cohort Study
Overview
Authors
Affiliations
Introduction: Corpus-restricted atrophic gastritis is a chronic inflammatory disorder leading to possible development of type 1 neuroendocrine tumors (T1gNET), intraepithelial neoplasia (IEN), and gastric cancer (GC). We aimed to assess occurrence and predictors of gastric neoplastic lesions in patients with corpus-restricted atrophic gastritis at long-term follow-up.
Methods: A prospective single-center cohort of patients with corpus-restricted atrophic gastritis adhering to endoscopic-histological surveillance was considered. Follow-up gastroscopies were scheduled according to the management of epithelial precancerous conditions and lesions of the stomach guidelines. In case of new/worsening of known symptoms, gastroscopy was anticipated. Cox regression analyses and Kaplan-Meier survival curves were obtained.
Results: Two hundred seventy-five patients with corpus-restricted atrophic gastritis (72.0% female, median age 61 [23-84] years) were included. At a median follow-up of 5 (1-17) years, the annual incidence rate person-year was 0.5%, 0.6%, 2.8%, and 3.9% for GC/high-grade IEN, low-grade IEN, T1gNET, and all gastric neoplastic lesions, respectively. All patients showed at baseline operative link for gastritis assessment (OLGA)-2, except 2 low-grade (LG) IEN patients and 1 T1gNET patient with OLGA-1. Age older than 60 years (hazard ratio [HR] 4.7), intestinal metaplasia without pseudopyloric metaplasia (HR 4.3), and pernicious anemia (HR 4.3) were associated with higher risk for GC/HG-IEN or LG-IEN development and shorter mean survival time for progression (13.4, 13.2, and 11.1, respectively, vs 14.7 years, P = 0.01). Pernicious anemia was an independent risk factor for T1gNET (HR 2.2) and associated with a shorter mean survival time for progression (11.7 vs 13.6 years, P = 0.04) as well as severe corpus atrophy (12.8 vs 13.6 years, P = 0.03).
Discussion: Patients with corpus-restricted atrophic gastritis are at increased risk for GC and T1gNET despite low-risk OLGA scores, and those aged older than 60 years with corpus intestinal metaplasia or pernicious anemia seem to display a high-risk scenario.
Wang Y, Li P, He H, Zhang F, Jiang X, Zhang R BMC Gastroenterol. 2025; 25(1):92.
PMID: 39966739 PMC: 11837693. DOI: 10.1186/s12876-025-03662-z.
Gao T, Ren M, Feng Y, Li Y, Zhang X, He S Lipids Health Dis. 2024; 23(1):398.
PMID: 39616367 PMC: 11607860. DOI: 10.1186/s12944-024-02321-8.
Autoimmune gastritis studies and gastric cancer: True renaissance or bibliometric illusion.
Isakov V World J Gastroenterol. 2024; 30(32):3783-3790.
PMID: 39221066 PMC: 11362875. DOI: 10.3748/wjg.v30.i32.3783.
Kishikawa H, Takarabe S, Ichikawa M, Sasaki A, Nishida J Cureus. 2024; 16(8):e66910.
PMID: 39148949 PMC: 11326753. DOI: 10.7759/cureus.66910.
Autoimmune Gastritis and Hypochlorhydria: Known Concepts from a New Perspective.
Vavallo M, Cingolani S, Cozza G, Schiavone F, Dottori L, Palumbo C Int J Mol Sci. 2024; 25(13).
PMID: 38999928 PMC: 11241626. DOI: 10.3390/ijms25136818.